Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Orders Revision of Package Inserts for Cetuximab, Panitumumab
April 3, 2015
- MHLW Requires Municipalities to Compile Generic Promotion Plans for Welfare Recipients
April 3, 2015
- AMED Inaugurated with Diverse Talents as Unit Heads
April 2, 2015
- MHLW Notifies of New Criteria for Orphan Drug Designation
April 2, 2015
- MHLW Notifications Prod Generic Use under High-Cost Healthcare Benefit System
April 2, 2015
- PMDA Sets Up New Unit to Promote Medical Database Project
April 1, 2015
- LDP Legislators Discuss Legal Regulation of Clinical Research
April 1, 2015
- MHLW to Invite Candidate Products for “Sakigake” Designation System
March 31, 2015
- MHLW Reiterates Caution on Skin Disorders for Lamictal: Safety Bulletin
March 31, 2015
- Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
- PMDA Launches Consultation Services for Academia-Led Trials
March 30, 2015
- MHLW OKs 32 Products Including Sovaldi, Lenvima
March 27, 2015
- Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
- Govt OKs AMED’s 5-Year Plan Articulating Support for 200 Drug Seed Development Projects
March 26, 2015
- Cabinet OKs NIBIO Director Yoneda as Chief of Merged Institute
March 25, 2015
- Ministry Requires Addition of Thrombocytopenia as Serious ADR to Januvia
March 25, 2015
- Lawmakers to Form Nonpartisan Group to Spur Biosimilar Use
March 24, 2015
- Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
March 24, 2015
- PMDA Pledges Cooperation to Promote Commercialization of Seeds: Chief Executive
March 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 9 - 22
March 23, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…